Feasibility of an Evidence-based Walking Program in Cancer Pts 60+ During Chemotherapy
- Conditions
- Colon CancerLung CancerBreast Cancer
- Interventions
- Behavioral: Walk With Ease ProgramOther: Collect Blood, GA and Other Survey Tools
- Registration Number
- NCT01789983
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Brief Summary
The study will look at conducting a medium-intense walking program called Walk With Ease with cancer patients age 60 and above who are starting chemotherapy treatment. We will measure how many of these patients complete their participation in this program.
- Detailed Description
The primary purpose of this study is to evaluate the feasibility of implementing a moderate-intensity walking program (Walk With Ease/WWE) among cancer patients, age ≥60 years, as they undergo cytotoxic chemotherapy treatment. Feasibility will be determined based on the rate of participation in the WWE program. As secondary objectives, we will also establish the rate of completion of a number of instruments, including a Geriatric Assessment tool, and other instruments that measure self-reported quality of life (e.g., fatigue, depression, and pain), and self-reported physical activity (PA). Data from these instruments, as well as from serial measurements of a biomarker of aging (p16INK4a) will be explored and used to inform future studies designed to evaluate any relationship between these variables and participation in the WWE program.
We propose a sample (n=30) of cancer patients ≥60 years of age with potentially curable cancer and a diagnosis of Stage I-III breast cancer, Stage I-III lung cancer, or Stage II-III colon cancer, who are about to begin chemotherapy. Participation will be defined as completing the 6-week WWE program. Results from this study will be used in an RO1 application to the National Cancer Institute (NCI) pertaining to PA interventions among cancer patients and the effects of biomarkers on prognosis and survival.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 29
- ≥60 years of age, male or female
- Histologically confirmed Stage I, II or III breast cancer (if the patient has had more than one breast cancer diagnosis, then the most recent diagnosis); Stage I, II or III lung cancer, or Stage II or III colon cancer
- Scheduled to begin a chemotherapy (or concomitant chemoradiotherapy) regimen that will last at least 6 weeks in duration
- English speaking
- IRB approved, signed written informed consent
- Approval from their treating physician to engage in moderate-intensity physical activity
- Patient-assessed ability to walk and engage in moderate physical activity
- Willing and able to meet all study requirements.
- One or more significant medical conditions that in the physician's judgment preclude participation in the walking intervention
- Cancer surgery scheduled within the study period
- Unable to walk or engage in moderate-intensity physical activity
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Breast Cancer Patients 60+ Walk With Ease Program Breast Cancer Patients age 60 and older who have histologically confirmed stage I, II or III disease. Breast Cancer Patients 60+ Collect Blood, GA and Other Survey Tools Breast Cancer Patients age 60 and older who have histologically confirmed stage I, II or III disease. Lung Cancer Patients 60+ Collect Blood, GA and Other Survey Tools Lung Cancer Patients age 60 and above who have stage I, II or III disease Colon Cancer Patients 60+ Walk With Ease Program Colon cancer patients age 60 and above who have stage II or III disease. Colon Cancer Patients 60+ Collect Blood, GA and Other Survey Tools Colon cancer patients age 60 and above who have stage II or III disease. Lung Cancer Patients 60+ Walk With Ease Program Lung Cancer Patients age 60 and above who have stage I, II or III disease
- Primary Outcome Measures
Name Time Method To measure the feasibility of implementing the WWE program among cancer patients, age ≥60, as they undergo cytotoxic chemotherapy treatment. 1 year Feasibility will be defined as the proportion of recruited subjects who complete the 6-week WWE program.
- Secondary Outcome Measures
Name Time Method To measure the rate of completion of each of the following questionnaires/assessments at 3 different time points 1 year The rate of completion of assessments will be measured at baseline, 6 weeks and end of chemotherapy treatment.
To measure relationships between physical activity levels and p16 levels. 1 year To measure the association between number of minutes walked per day and number of times per week with p16 levels.
Trial Locations
- Locations (1)
University of North Carolina Cancer Hospital
🇺🇸Chapel Hill, North Carolina, United States